Area of research
Radiology, Nuclear Medicine and Imaging · Oncology
Research interest
Research interests include Radiopharmaceutical Chemistry and Applications, Monoclonal and Polyclonal Antibodies Research, Peptidase Inhibition and Analysis, and Prostate Cancer Treatment and Research.
A versatile silica nanoparticle platform for induction of T cell responses – applied for therapeutic vaccination against HPV16 E6/E7-positive tumors in MHC-humanized mice
Feasibility, Tolerability, and Preliminary Clinical Response of Fractionated Radiopharmaceutical Therapy with<sup>213</sup>Bi-FAPI-46: Pilot Experience in Patients with End-Stage, Progressive Metastatic Tumors
Conjugation of Polycationic Peptides Extends the Efficacy Spectrum of β‐Lactam Antibiotics
Non-cross-linking advanced glycation end products affect prohormone processing
Impact of Linker Modification and PEGylation of Vancomycin Conjugates on Structure-Activity Relationships and Pharmacokinetics
Refined Chelator Spacer Moieties Ameliorate the Pharmacokinetics of PSMA-617
[153Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma
18F-labeled tracers targeting fibroblast activation protein
FAP imaging in rare cancer entities—first clinical experience in a broad spectrum of malignancies
Design and Development of <sup>99m</sup>Tc-Labeled FAPI Tracers for SPECT Imaging and <sup>188</sup>Re Therapy
Vancomycin Resistance Is Overcome by Conjugation of Polycationic Peptides
Improving antibody-based therapies by chemical engineering of antibodies with multimeric cell-penetrating peptides for elevated intracellular delivery
Vancomycin-Lipopeptide Conjugates with High Antimicrobial Activity on Vancomycin-Resistant Enterococci
Überwindung von Vancomycinresistenzen durch Modifikation mit polykationischen Peptiden
Ga-68-FAPI PET/CT: Ein Überblick zum Tracer-Uptake bei 28 unterschiedlichen Tumorentitäten
Fluor-18-markierte FAPI-Tracer für die PET-Bildgebung
Inside Back Cover: Vancomycin Resistance Is Overcome by Conjugation of Polycationic Peptides (Angew. Chem. Int. Ed. 23/2020)
Innenrücktitelbild: Überwindung von Vancomycinresistenzen durch Modifikation mit polykationischen Peptiden (Angew. Chem. 23/2020)
<sup>68</sup>Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer
Development of Fibroblast Activation Protein–Targeted Radiotracers with Improved Tumor Retention
Development and dosimetry of 203Pb/212Pb-labelled PSMA ligands: bringing “the lead” into PSMA-targeted alpha therapy?
Carbon irradiation overcomes glioma radioresistance by eradicating stem cells and forming an antiangiogenic and immunopermissive niche
Response Prediction of <sup>177</sup>Lu-PSMA-617 Radioligand Therapy Using Prostate-Specific Antigen, Chromogranin A, and Lactate Dehydrogenase
Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes
PET/CT Imaging of NSCLC with a αvβ6 Integrin-Targeting Peptide
DNA damage in human whole blood caused by radiopharmaceuticals evaluated by the comet assay
Preclinical evaluation of peptide-based radiotracers for integrin αvβ6-positive pancreatic carcinoma
Reduction of salivary gland uptake in endoradiotherapy of prostate cancer: first preclinical data of a cleavable derivative of PSMA-617
2019cited by 2position: middle
Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein
A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts